Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shuren: LDT Reliability Critical To Precision Medicine Initiative

This article was originally published in The Pink Sheet Daily

Executive Summary

The head of FDA's device center said the agency's efforts to oversee laboratory developed tests are critical to ensuring reliability of genetic tests in conjunction with the president's Precision Medicine Initiative.

You may also be interested in...



Clinical Labs Lawyer Up In Battle Over LDTs

ACLA has recruited Laurence Tribe and Paul Clement, two prominent constitutional legal guns with Supreme Court expertise, to fight FDA over its proposed lab-developed test guidance. The announcement is perhaps the lab industry's most high profile move yet to oppose FDA's plan to regulate lab-developed test services under the device statute with a risk-based phase-in plan.

FDA Releases LDT Regulatory Framework, Notification Draft Guidances

Two promised draft guidances on FDA’s framework for regulating laboratory developed tests and notification and medical device reporting requirements for LDTs have been posted. The agency wants swift notification from labs for most available LDTs once a framework is finalized.

Experts: COVID-19, Departure Of Key FDA Staff Likely Contributing Factors For Delayed AI/ML Action Plan

The recent artificial intelligence/machine learning software action plan released by the US agency took nearly two years to develop.

Topics

UsernamePublicRestriction

Register

OM017301

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel